AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT03071016
- Locations
- 🇮🇳
Research Site, Kolkata, West Bengal, India
Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
- Conditions
- PSR Ovarian Cancer With a BRCA Mutation
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03063710
- Locations
- 🇯🇵
Research Site, Chuo-ku, Tokyo, Japan
Outcomes in UK ACS Patients Prescribed Ticagrelor
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1650
- Registration Number
- NCT03058601
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
Phase 4
Completed
- Conditions
- Opioid Induced Constipation
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT03060512
- Locations
- 🇺🇸
Research Site, West Jordan, Utah, United States
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Patient Reported Outcomes
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 89
- Registration Number
- NCT03053297
- Locations
- 🇬🇧
Research Site, Worcester, United Kingdom
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Phase 3
Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma Extensive Disease
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 987
- Registration Number
- NCT03043872
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
XIGDUO Extended Release (XR) Post Marketing Surveillance
Completed
- Conditions
- Adult Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 623
- Registration Number
- NCT03038789
- Locations
- 🇰🇷
Research Site, WonJu, Korea, Republic of
Asia PDL1 Study Among NSCLC Patients
Completed
- Conditions
- Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 658
- Registration Number
- NCT03037086
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4304
- Registration Number
- NCT03036150
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
Phase 3
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4744
- Registration Number
- NCT03036124
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath